Abstract
Neuroimaging in Parkinson's disease (PD) and other primary Parkinsonian disorders has been increasingly used in the routine clinical work in the last years. The paradigm has changed from an "exclusionary" use, i.e., to rule out causes of secondary Parkinsonism, to an "inclusionary" one, i.e., finding image and network characteristics allowing to identify a specific disease. This is allowed by analyses spanning from the commonly used visual analysis to the most sophisticated postprocessing leading to the identification of covariance patterns both in morphological and functional neuroimaging. However, paralleling the advancement in covariance and connectivity analyses, the issues of standardization and harmonization of data acquisition, and image reconstruction and postprocessing among centers are emerging in the scientific community. Also, the building of scientific evidence still suffers from the lack of large, formal studies and relies on relatively small cohort studies from one or few centers. Joint actions to face these issues are now ongoing in Europe, supported by specific programs, such as the Joint Programming on Neurodegenerative Diseases (JPND). In the present review, some of the most recent and relevant achievements in the field of diffusion tensor magnetic resonance imaging (MRI), functional MRI, fludeoxyglucose-positron-emission tomography, dopamine transporter single-photon emission computed tomography and non-dopaminergic imaging in PD and primary Parkinsonisms are reported.
| Original language | English |
|---|---|
| Pages (from-to) | 372-385 |
| Number of pages | 14 |
| Journal | Quarterly Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 61 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Dec 1 2017 |
Fingerprint
Keywords
- Emission-computed
- Fluorodeoxyglucose F18
- Magnetic resonance imaging
- Parkinson disease
- Parkinsonian disorders
- Positron-emission tomography
- Single-photon
- Tomography
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Clinical utility and research frontiers of neuroimaging in movement disorders. / Nobili, Flavio; Westman, Eric; Kogan, Rosalie V.; Pereira, Joana B.; Massa, Federico; Grazzini, Matteo; Meles, Sanne K.; Leenders, Klaus L.
In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 61, No. 4, 01.12.2017, p. 372-385.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Clinical utility and research frontiers of neuroimaging in movement disorders
AU - Nobili, Flavio
AU - Westman, Eric
AU - Kogan, Rosalie V.
AU - Pereira, Joana B.
AU - Massa, Federico
AU - Grazzini, Matteo
AU - Meles, Sanne K.
AU - Leenders, Klaus L.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Neuroimaging in Parkinson's disease (PD) and other primary Parkinsonian disorders has been increasingly used in the routine clinical work in the last years. The paradigm has changed from an "exclusionary" use, i.e., to rule out causes of secondary Parkinsonism, to an "inclusionary" one, i.e., finding image and network characteristics allowing to identify a specific disease. This is allowed by analyses spanning from the commonly used visual analysis to the most sophisticated postprocessing leading to the identification of covariance patterns both in morphological and functional neuroimaging. However, paralleling the advancement in covariance and connectivity analyses, the issues of standardization and harmonization of data acquisition, and image reconstruction and postprocessing among centers are emerging in the scientific community. Also, the building of scientific evidence still suffers from the lack of large, formal studies and relies on relatively small cohort studies from one or few centers. Joint actions to face these issues are now ongoing in Europe, supported by specific programs, such as the Joint Programming on Neurodegenerative Diseases (JPND). In the present review, some of the most recent and relevant achievements in the field of diffusion tensor magnetic resonance imaging (MRI), functional MRI, fludeoxyglucose-positron-emission tomography, dopamine transporter single-photon emission computed tomography and non-dopaminergic imaging in PD and primary Parkinsonisms are reported.
AB - Neuroimaging in Parkinson's disease (PD) and other primary Parkinsonian disorders has been increasingly used in the routine clinical work in the last years. The paradigm has changed from an "exclusionary" use, i.e., to rule out causes of secondary Parkinsonism, to an "inclusionary" one, i.e., finding image and network characteristics allowing to identify a specific disease. This is allowed by analyses spanning from the commonly used visual analysis to the most sophisticated postprocessing leading to the identification of covariance patterns both in morphological and functional neuroimaging. However, paralleling the advancement in covariance and connectivity analyses, the issues of standardization and harmonization of data acquisition, and image reconstruction and postprocessing among centers are emerging in the scientific community. Also, the building of scientific evidence still suffers from the lack of large, formal studies and relies on relatively small cohort studies from one or few centers. Joint actions to face these issues are now ongoing in Europe, supported by specific programs, such as the Joint Programming on Neurodegenerative Diseases (JPND). In the present review, some of the most recent and relevant achievements in the field of diffusion tensor magnetic resonance imaging (MRI), functional MRI, fludeoxyglucose-positron-emission tomography, dopamine transporter single-photon emission computed tomography and non-dopaminergic imaging in PD and primary Parkinsonisms are reported.
KW - Emission-computed
KW - Fluorodeoxyglucose F18
KW - Magnetic resonance imaging
KW - Parkinson disease
KW - Parkinsonian disorders
KW - Positron-emission tomography
KW - Single-photon
KW - Tomography
UR - http://www.scopus.com/inward/record.url?scp=85031942264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031942264&partnerID=8YFLogxK
U2 - 10.23736/S1824-4785.17.03018-7
DO - 10.23736/S1824-4785.17.03018-7
M3 - Review article
AN - SCOPUS:85031942264
VL - 61
SP - 372
EP - 385
JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging
JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging
SN - 1824-4785
IS - 4
ER -